[ad_1]
The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to provide up to $ 328 million to Clover Biopharmaceuticals for the development of the Covid-19 candidate vaccine.
Clover will use the funds to conduct the pivotal Phase 2/3 global efficacy clinical trial of the S-Trimer Covid-19 protein-based candidate vaccine. It will also use the funds to license the vaccine in China and around the world.
The investment also includes previously announced commitments of $ 69.5 million, which have been used for phase 1 clinical trials and studies, preparations for the fundamental phase 2/3 global efficacy study, and initial manufacturing scaling-up activities.
S-Trimer, which uses advanced Trimer-Tag technology, is a candidate for a trimeric SARS-CoV-2 peak protein subunit (S) vaccine. S-Trimer is generated through a fast mammalian cell culture based expression system.
CEPI’s expanded partnership builds on Clover’s successful early-stage clinical development of the S-Trimer vaccine candidate.
The funding will be used for a pivotal phase 2/3 global efficacy clinical trial of S-Trimer, expected to begin later this year. The data from the trial will be used to obtain a license for the candidate vaccine.
Clover will also use funds to conduct additional clinical studies in special populations such as people with autoimmune diseases, immunosuppressed people, pregnant women and children.
The program will also focus on expanding the manufacturing process to facilitate the production of more than 1 billion doses per year, in parallel with the clinical development process.
After proving that it is safe, the S-Trimer vaccine will be provided through the COVAX Facility, a global initiative that helps procure and distribute two billion doses of the Covid-19 vaccine by the end of 2021.
Dr. Richard Hatchett, CEO of CEPI, said: “The clinical development and manufacturing progress of the Clover S-Trimer vaccine candidate vaccine is very promising so far, so I am pleased to extend our partnership with Clover. until the possible license of the vaccine “.
In February this year, GlaxoSmithKline (GSK) collaborated with the Chinese company Clover Biopharmaceuticals to evaluate the candidate for a coronavirus vaccine with the pandemic adjuvant system.
